Literature DB >> 3280280

Postmarketing surveillance methodologies.

S A Edlavitch1.   

Abstract

This article describes and discusses the strengths and limitations of the major pharmacoepidemologic methodologies employed in postmarketing drug surveillance and describes the current status of the U.S. surveillance system. The main methodologies employed in postmarketing drug surveillance include controlled clinical trials, observational epidemiologic studies (cohort, case-control, cross-sectional), demographic methods, drug utilization surveys, spontaneous reports, and automated databases linking medications and disease. Examples of pharmacoepidemiologic studies using each of these methodologies are presented. When a question arises about the efficacy and/or safety of a marketed drug, typically a mixture of these study methodologies is employed. The article concludes with a brief discussion of the role of the Food and Drug Administration, pharmaceutical manufactures, and academic institutions in initiating and conducting postmarketing drug studies.

Mesh:

Year:  1988        PMID: 3280280     DOI: 10.1177/106002808802200117

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

Review 1.  Pharmacovigilance: towards a better understanding of the benefit to risk ratio.

Authors:  L S Simon
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

Review 3.  Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

4.  Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia.

Authors:  Mansour Adam Mahmoud; Yazed Alsowaida; Thamir Alshammari; Tahir Mehmood Khan; Alian Alrasheedy; Mohamad Azmi Hassali; Hisham Aljadhey
Journal:  Saudi Pharm J       Date:  2013-08-21       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.